Skip to content

News

Trends in the Receipt of Guideline Care and Survival for Wo...

Trends in the Receipt of Guideline Care and Survival for Women with Ovarian Cancer: A Population-Based Study

(April 20, 2017) Researchers from the National Cancer Institute assessed trends in the receipt of guideline care and 2-year cause-specific survival for women diagnosed with ovarian cancer. The study included 6427 women diagnosed in 2002 and in 2011. • The adjusted rate of women who received stage-appropriate surgery, 48%, was unchanged from 2002 to 2011. … Continued

Research

Random Mutations Play Major Role in Cancer

Random Mutations Play Major Role in Cancer

(April 7, 2017) A major new study published in Science claims that the reason why many people get cancer is simply just bad luck. It’s normal for people to seek a reason when someone develops cancer (did he smoke? Was it hereditary?), and certainly lifestyle factors can play a major role in the development of … Continued

Research

Niraparib Approved for Maintenance Treatment of Ovarian Cancer

Niraparib Approved for Maintenance Treatment of Ovarian Cancer

(March 28, 2017) The U.S. Food and Drug Administration approved niraparib (ZEJULA, TESARO, Inc.), poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib is the first PARP inhibitor to be approved … Continued

Research

Research Updates from 2017 SGO Annual Meeting

Research Updates from 2017 SGO Annual Meeting

(March 23, 2017) OCRFA staff and volunteers recently attended the Society of Gynecologic Oncology’s (SGO) Annual Meeting on Women’s Cancer, held March 11-14, 2017 in Maryland. Every year women’s cancer physicians and researchers gather at this meeting to discuss the latest in the care and treatment of women with ovarian and other gynecologic cancers. OCRFA … Continued

Research

Screening High-Risk Women Catches More Early Stage Ovarian ...

Screening High-Risk Women Catches More Early Stage Ovarian Cancers

(March 15, 2017) Results from a large study showed that screening for ovarian cancer in high-risk patients led to detection of significantly more early-stage disease as compared with the year after screening ended. However, it is not yet known whether this screening approach would improve survival in screened high-risk women. The results of the study … Continued

Research

Hormone Therapy Improves Survival of Low Grade Serous Carci...

Hormone Therapy Improves Survival of Low Grade Serous Carcinoma Patients

(March 6, 2017) A team from University of Texas MD Anderson Cancer Center, including OCRFA Scientific Advisory Committee Member Dr. Robert Coleman, published a study in Journal of Clinical Oncology about the effect of hormonal therapy on a rare type of ovarian cancer. The use of hormone maintenance therapy (HMT) with low-grade serous carcinoma (LGSC), … Continued

OCRA News

OCRFA Research Finds New Gene Mutation Spurs Cancer Growth

OCRFA Research Finds New Gene Mutation Spurs Cancer Growth

(February 7, 2017) An OCRFA funded study, published on January 13, 2017 in Oncotarget, sheds light on EMSY, a gene that researchers at New York University Langone Medical Center now understand to have a role similar to those of BRCA1 and BRCA2. BRCA1 and BRCA2 are well known genes that, when working, help with DNA … Continued

OCRA News

Rucaparib Extends PFS in Ovarian Cancer

Rucaparib Extends PFS in Ovarian Cancer

(February 3, 2017) Results from the ARIEL2 trial, funded in part by OCRFA’s grant to the Stand Up to Cancer Ovarian Cancer Dream Team, were recently published in The Lancet. The goal of the trial was to test if the efficacy of rucaparib, an oral PARP inhibitor, was dependent on the type of tumor mutation. … Continued

OCRA News

OCRFA Funded Research Studies DNA Repair in Ovarian Cancer ...

OCRFA Funded Research Studies DNA Repair in Ovarian Cancer Cells

(January 30, 2017) In a study funded in part by OCRFA, and published this month in Oncotarget, researchers, including first author and former OCRFA grantee Petar Jelinic, PhD, studied EMSY, a putative BRCAness gene, and its role in the suppression of DNA damage repair in ovarian cancer cells. The EMSY gene is amplified in approximately … Continued

OCRA News

OCRFA Awards $5.6 Million in Scientific Research Grants for...

OCRFA Awards $5.6 Million in Scientific Research Grants for 2017

(January 20, 2017) OCRFA has awarded $5.6 million in new scientific research grants for ovarian cancer, bringing our total investment in life-saving research to over $75 million. This year’s grants have been awarded to twenty top scientists at thirteen leading medical centers across the country. “Our 2017 grantees are among the best and brightest working … Continued

OCRA News

Now Accepting Applications for 2017 Community Partners

Now Accepting Applications for 2017 Community Partners

OCRFA’s Community Partners (formerly called Partner Members) are outstanding grassroots, local and national organizations around the country who share a commitment to eradicate ovarian cancer through research, advocacy, support, education and awareness. The goal of our Community Partners initiative is to unite the ovarian cancer community into a national movement speaking with one voice through … Continued

Community

Now Accepting Scholarship Applications for 2017 Ovarian Can...

Now Accepting Scholarship Applications for 2017 Ovarian Cancer National Conference

Update: The 2017 Scholarship Application closed on April 2, 2017. Our scholarship program allows patients and caregivers to learn about ovarian cancer and connect with others who share their experiences. In 2016, thanks to the generosity of donors, our scholarship program helped 40 individuals attend our National Conference. A limited number of scholarships for registration … Continued

Community

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.